Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 4
2010 3
2011 4
2012 2
2013 1
2014 3
2015 1
2016 1
2017 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D. Kontopodis E, et al. Among authors: christophyllakis ch. Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15. Cancer Chemother Pharmacol. 2015. PMID: 25398698 Clinical Trial.
Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulias V, Mavroudis D. Vetsika EK, et al. Among authors: christophyllakis c. J Immunother. 2011 Nov-Dec;34(9):641-50. doi: 10.1097/CJI.0b013e31823284a6. J Immunother. 2011. PMID: 21989412
Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V. Karampeazis A, et al. Among authors: christophyllakis c. Clin Lung Cancer. 2011 May;12(3):155-60. doi: 10.1016/j.cllc.2011.03.015. Epub 2011 Apr 27. Clin Lung Cancer. 2011. PMID: 21663857 Clinical Trial.
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Tryfonidis K, et al. Among authors: christophyllakis c. Breast. 2013 Dec;22(6):1171-7. doi: 10.1016/j.breast.2013.08.017. Epub 2013 Oct 1. Breast. 2013. PMID: 24091128 Free article. Clinical Trial.
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S. Pallis AG, et al. Among authors: christophyllakis c. Clin Lung Cancer. 2011 Mar;12(2):100-5. doi: 10.1016/j.cllc.2011.03.004. Epub 2011 Apr 11. Clin Lung Cancer. 2011. PMID: 21550556 Clinical Trial.
Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.
Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D. Kotsakis A, et al. Among authors: christophyllakis ch. Ann Oncol. 2012 Feb;23(2):442-9. doi: 10.1093/annonc/mdr396. Epub 2011 Aug 25. Ann Oncol. 2012. PMID: 21873272 Free article. Clinical Trial.
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S. Xenidis N, et al. Among authors: christophyllakis ch. Lung Cancer. 2010 Jun;68(3):450-4. doi: 10.1016/j.lungcan.2009.08.012. Epub 2009 Sep 23. Lung Cancer. 2010. PMID: 19783319 Clinical Trial.
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A. Souglakos J, et al. Among authors: christophyllakis ch. Br J Cancer. 2012 Jan 31;106(3):453-9. doi: 10.1038/bjc.2011.594. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240792 Free PMC article. Clinical Trial.
Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.
Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V. Karampeazis A, et al. Among authors: christophyllakis c. J Geriatr Oncol. 2017 Jan;8(1):23-30. doi: 10.1016/j.jgo.2016.05.002. Epub 2016 Jun 2. J Geriatr Oncol. 2017. PMID: 27264267
15 results